Cargando…

Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis

INTRODUCTION: One target of rheumatoid arthritis (RA) treatment is to achieve early sustained remission; over the long term, patients in sustained remission have less structural joint damage and physical disability. We evaluated Simplified Disease Activity Index (SDAI) remission with abatacept + met...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emery, Paul, Tanaka, Yoshiya, Bykerk, Vivian P., Huizinga, Thomas W. J., Citera, Gustavo, Bingham, Clifton O., Banerjee, Subhashis, Soule, Benjamin P., Nys, Marleen, Connolly, Sean E., Lozenski, Karissa L., Zhuo, Joe, Wong, Robert, Huang, Kuan-Hsiang Gary, Fleischmann, Roy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140217/ https://www.ncbi.nlm.nih.gov/pubmed/36869251 http://dx.doi.org/10.1007/s40744-022-00519-9

Ejemplares similares

The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study
por: Emery, Paul, et al.
Publicado: (2023)

Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis
por: Wu, Chun, et al.
Publicado: (2022)

Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept
por: Ahmad, Harris A., et al.
Publicado: (2022)

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study
por: Emery, Paul, et al.
Publicado: (2019)

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus
por: Alten, Rieke, et al.
Publicado: (2023)

Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment
por: Westhovens, R, et al.
Publicado: (2004)

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
por: Emery, Paul, et al.
Publicado: (2015)

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
por: Mease, Philip J, et al.
Publicado: (2017)

HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA
por: Rigby, William, et al.
Publicado: (2021)

Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials
por: Simon, Teresa A., et al.
Publicado: (2019)

Benefits of Autoantibody Enrichment in Early Rheumatoid Arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials
por: Michaud, Kaleb, et al.
Publicado: (2023)

Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study
por: Jansen, Diahann T S L, et al.
Publicado: (2018)

Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study
por: Alten, Rieke, et al.
Publicado: (2022)

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis
por: Peterfy, Charles, et al.
Publicado: (2016)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011)

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
por: Schiff, Michael, et al.
Publicado: (2011)

Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2021)

Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)
por: Smolen, Josef S., et al.
Publicado: (2015)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan
por: Takeuchi, Tsutomu, et al.
Publicado: (2015)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
por: Weinblatt, Michael E, et al.
Publicado: (2013)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
por: Schiff, Michael, et al.
Publicado: (2014)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
por: Alten, Rieke, et al.
Publicado: (2016)

A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?
por: Harrold, Leslie R., et al.
Publicado: (2017)

Gene expression regulated by abatacept associated with methotrexate and correlation with disease activity in rheumatoid arthritis
por: Derambure, Céline, et al.
Publicado: (2020)

Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study
por: Matsubara, Tsukasa, et al.
Publicado: (2018)

Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate
por: Benucci, Maurizio, et al.
Publicado: (2017)

Molluscum contagiosum eruption during therapy with methotrexate and abatacept: A clinical and dermoscopic case study
por: Taviti, Franca, et al.
Publicado: (2022)

Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis
por: Guyot, Patricia, et al.
Publicado: (2011)

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
por: Kavanaugh, Arthur, et al.
Publicado: (2013)

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
por: Westhovens, R, et al.
Publicado: (2009)

Brief Report: Estimating Disease Activity Using Multi‐Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab
por: Fleischmann, Roy, et al.
Publicado: (2016)

Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial
por: Baer, Alan N, et al.
Publicado: (2021)

Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab
por: Talmon, Maria, et al.
Publicado: (2023)

Joint Estimation of Remission and Response for Methotrexate‐Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta‐Analysis
por: Pokharel, Gyanendra, et al.
Publicado: (2019)

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial
por: Strand, Vibeke, et al.
Publicado: (2018)

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis
por: Mease, Philip J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5l6bvv32t3ir7pj8bt5o46pro7